Market Trends of Global NGS Sample Preparation Industry
This section covers the major market trends shaping the NGS Sample Preparation Market according to our research experts:
Diagnostics Segment is Expected to Witness Considerable Growth Over the Forecast Period
NGS can sequence hundreds and thousands of genes or whole genomes quickly. The sequence variants/mutations detected by NGS have been widely used for disease diagnosis, prognosis, therapeutic decision, and follow-up of patients.
The research and treatment of cancer have been transformed by next-generation sequencing to a great extent. The NGS of individual cancerpatient genomes is carried out using NGS base genomic sequencing, and it has emerged as one of the fastest and less expensive methods. For instance, in August 2021, the European Society for Medical Oncology (ESMO), the medical oncology professional organization, launched its first recommendations on the use of next-generation sequencing (NGS) for patients with metastatic cancers. According to ESMO recommendations, NGS could be an alternative to Polymerase Chain Reaction (PCR) in colon cancers. NGS can be suitable for identifying multiple genes and their mutations concurrently by sequencing millions of DNA reads and driving therapeutic decision-making. This is projected to increase in adoption of next-generation sequencing sample preparation for drug development.
The advancements in technology, increasing product approvals and launches, partnerships, and collaborations by key players are also driving growth in the diagnostics segment. For instance, in February 2021, QIAGEN and INOVIO expanded their partnership to create a companion diagnostic using next-generation sequencing (NGS) for INOVIO's VGX-3100 for advanced cervical dysplasia. Furthermore, in Aug 2020, Guardant Health Inc. received the United States Food and Drug Administration (FDA) approval for Guardant360 CDx, which uses two combined technology, Liquid biopsy, and NGS, in one diagnostic test. Hence, the increasing product approval related to NGS diagnostic and product launches may create new opportunities for the segment, owing to which considerable segment growth is anticipated over the forecast period.
North America is Expected to Witness Significant Growth Over the Forecast Period
North America is expected to witness considerable market growth owing to factors such as the rising need for diagnostics tools for identifying health disparities, and the rising burden of infectious diseases and chronic diseases in the region. The increasing technological advancement, product launches, partnerships, and acquisitions by the key market players are leading to an increase in market growth in North America. For instance, in January 2022, Illumina Inc. and Nashville Biosciences LLC, a subsidiary of Vanderbilt University Medical Center (VUMC), entered a multi-year agreement to accelerate medicines development through large-scale genomics and the establishment of a clinical-genomic resource using Illumina's next-generation sequencing (NGS) platforms. Such initiatives are expected to drive the growth of the NGS sample preparation market in North America.
Key product launches, high concentration of market players or manufacturer's presence, and acquisition & partnerships among major players, and increased funding from the federal government and private players, as well as increased adoption of NGS technology by non-government and government bodies in the United States, are some of the factors driving the growth of the NGS sample preparation market in the country. For instance, in April 2021, Resolution Bioscience, a leader in the research and commercialization of next-generation sequencing (NGS)-based precision oncology solutions, has been acquired by Agilent Technologies. Similarly, in January 2020, in the United States, the Intelligence Advanced Research Projects Activity provided USD 23.0 million to the Broad Institute and Harvard University, and DNA Script. The organizations have been working together to explore the possibility of combining the enzymatic DNA synthesis technology and NGS into a single instrument for more than four years. Therefore, such positive developments are anticipated to boost the market growth in the United States over the forecast period.
